Acadia Pharma (ACAD) Announces Phase 3 Development Candidate ACP-101 for Prader-Willi Syndrome streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Acadia acquired Levo Therapeutics and worldwide rights to ACP-101 in June 2022 ACP-101 is a selective oxytocin-receptor agonist for the treatment of hyperphagia in Prader-Willi syndrome . | June 13, 2023
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.